{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-022408","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.015056+00:00","generated_at":"2026-06-28T11:10:27.609959+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vericel Q3 revenue up 7% to $34.5M; guides FY2021 revenue $158-$161M","bullets":["Q3 total net revenue $34.5M (+7% YoY); MACI $23.9M, Epicel $9.8M (+48% YoY).","Q3 net loss $4.9M ($0.11/sh) vs net income $3.6M in Q3 2020; non-GAAP adj. EBITDA $4.3M.","FY2021 guidance: revenue $158-$161M (27-30% YoY growth); gross margin ~70%; adj. EBITDA margin ~22%.","Cash and investments $119M, no debt; operating cash flow $3.6M in Q3.","NexoBrid BLA resubmission expected mid-2022; MACI biopsies growth >30% expected in 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-022408","json":"https://secwatch.observer/filing/0001628280-21-022408.json","markdown":"https://secwatch.observer/filing/0001628280-21-022408.md","text":"https://secwatch.observer/filing/0001628280-21-022408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828021022408/0001628280-21-022408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828021022408/vcel-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:10:27.609959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}